This spring, the Supreme Court of Canada (SCC) will consider the scope of patentable subject-matter as it relates to “methods ...

Expenses incurred by a generic drug manufacturer in defending Hatch-Waxman patent litigation are deductible as ordinary and necessary business expenses, the U.S. Court of Appeals for the Federal ...

Nathan Mammen and Cole Tipton of Snell & Wilmer LLP address the question as to how AI could affect or even upend determining ...

In 2021, the 30.7 million beneficiaries accounted for over $2 billion in payments for the 101 generic drugs. Under the ...

The Patent Term Extension (PTE) provisions of 35 U.S.C. § 156 compensate pharmaceutical patent owners for time they are not ...

Prometric, a global leader in professional and educational assessment, has achieved a major industry milestone by securing the first U.S. patent for AI-powered item generation technology. The patent—U ...

Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Google has a new policy proposal regarding AI and copyright, but it sounds like Google just wants to rewrite the rules in its ...

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...